Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series

Clicks: 7
ID: 326373
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #116 of 219 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Idiopathic inflammatory myopathy (IIM) is an orphan systemic disorder with muscular, cutaneous and pulmonary involvement. B cell-directed therapies, including rituximab, belimumab, and CAR-T have shown promise in altering disease outcome. We report the benefit of obinutuzumab in refractory myositis patients with Methods Northwell Rheumatology database was searched for obinutuzumab treated patients (2019–2024); five of them met 2017 EULAR/ACR classification criteria for IIM and were included in the analysis. Demographic, clinical, serological, and imaging data were collected. Overall response was rated as complete, partial, or no response based on clinical response and physician global assessment. Total improvement score (TIS) was not calculated because data was collected retrospectively. Descriptive statistics were used for analyses. Results Of five patients, 2 had antisynthetase syndrome, 1 dermatomyositis, and 2 overlap myositis. Most patients failed at least 3 immunosuppressive agents. The reason for obinutuzumab use was rituximab allergy and worsening of interstitial lung disease (ILD) and myositis activity (3/5), arthritis (2/5), and severe rash (1/5 patients), despite rituximab. After obinutuzumab 80% of patients had overall improvement by 3-6 months. Respiratory status improved/stabilized in all ILD patients. Two patients required second obinutuzumab cycle: one for recurrence and another for persistent disease with B cell re-population. One was lost to follow-up after second cycle and was deemed a nonresponder. At last observation 4/5 patients achieved complete response. No hypogammaglobulinemia, significant infections, or hospitalizations were observed. Conclusion Obinutuzumab was safe and provided durable improvement in difficult-to-treat myositis patients with rituximab allergy, further highlighting targeting B-cell pathway.
Reference Key
openalex_W7204184435 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ivana Ilić, Sonali Narain, Galina Marder
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag435
URL
https://doi.org/10.1093/rheumatology/keag435
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.